Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OrbiMed Invests $8 Million In Response Biomedical To Reap Rewards Of China's Rapid Growth POCT Market

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Life sciences and health investment firm OrbiMed recently injected $8 million in Response Biomedical, a Vancouver-based company providing rapid test products based on its RAMP platform and targeting the rapid growth of China's point-of-care testing market

You may also be interested in...

With Investment In Bharat Serum, OrbiMed Speeds Up Its Second Deal In India In Four Months

MUMBAI - The world's largest healthcare fund OrbiMed seems to be in a hurry to invest in emerging Indian companies. Less than four months after the nearly $5 billion fund made its debut with investments in the Southern Indian clinical research outfit Ecron Acunova, it has now struck its second deal with Bharat Serums and Vaccines - a mid-sized biopharmaceutical unit that mainly manufactures niche life-saving injectable drugs

Global VC OrbiMed Leads Series A Financing In Its Second China Start-up Investment

SHANGHAI - Life sciences and health investment firm OrbiMed announced March 8 that it has led $6.6 million series A financing for Chinese dental company EA Inc., which is focusing on providing invisible orthodontic braces to China's rising middle class

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts